Andrew Voronkov

Experience

• 

  Moscow government

  Jun 2003 - Aug 2004

  Consultant
• 

  Moscow State University

  Nov 2005 - Jan 2010

  • Postdoctoral fellow

    Jan 2009 - Jan 2010

  • PhD student

    Nov 2005 - Nov 2008
• 

  Chemical Diversity Research Institute

  Jan 2008 - Sept 2008

  Senior business development specialist

  Drug discovery project investments, elaboration of development strategy for russian pharmaceuticals industry until 2020. Web portal creation.

• 

  Rikshospitalet, Oslo universitetssykehus HF

  Nov 2009 - Nov 2013

  Postdoctoral fellow

  In silico drug discovery, stem cells, Wnt, Shh pathways. Tankyrase small molecule inhibitors drug design and development. Hit to lead optimization and hit optimization. ADME/Tox optimization. DMPK studies and optimization. Preclinical drug optimization.Molecular modelling Molecular dynamics (software AMBER, GROMAS, NAMD, Desmond)of protein and protein-ligand complexes (tankyrase in complex with small molecule inhibitors, complexes of Frizzled receptors with small molecules), amyloid beta and Frizzled receptors in lipid bilayers, molecular mechanics, homology-based modelling. De novo 3D protein structures modelling (Rosetta), homology-based modelling (Modeller), molecular mechanics methods.Chemoinformatics QSAR/QSPR model development and usage for activity predictionand virtual screening. Machine-learning methods (artificial neuronal networks, naive Bayes classifiers, SVM, k-Nearest Neighbors, Ant colony and Random Forest). Regression analysis, principal component analysis. 3D- QSAR methods: ComFA, CoMSIA, Open3D QSAR. 2D-QSAR: Molecular Field Topology Analysis (MFTA). Calculation and usage of different structure-based and property- based molecular descriptors. Show less

• 

  Drugdiscovery@home project (non-profit initiative)

  Jan 2010 - May 2016

  DrugDiscovery@Home volunteer distributed computing project for different in silico drug design applications. If you need a computational power for your tasks and applications - get in contact with us.Our recent update will cover blockchain and Ethereum-backed smart-contracts with computing power generation through BOINC. Non-commercial project for volunteer computing

  • Project leader

    Jan 2009 - May 2016

  • Project leader

    Jan 2010 - Jan 2010
• 

  IVAO inc.

  Dec 2012 - Mar 2017

  R&D director

  Our company is working in the field of investments into biomedicine. We are looking for the research projects in the fields of aging and age-related diseases. We are also interested in making shares portfolio of companies, working in these fields and provide these portfolios to ideological investors, which want to invest into public companies, working in the field of aging and age-related diseases.

• 

  Digital BioPharm ltd.

  Sept 2014 - Apr 2016

  Executive director&founder

  Consulting company in the next fields:- Early stage drug discovery- In silico technologies in drug development- Grid and distributed volunteer computing- Investment consulting in the fields of pharmaceutics and IT (due diligence)Molecular modelling Molecular dynamics (software AMBER, GROMAS, NAMD, Desmond)of protein and protein-ligand complexes (tankyrase in complex with small molecule inhibitors, complexes of Frizzled receptors with small molecules), amyloid beta and Frizzled receptors in lipid bilayers, molecular mechanics, homology-based modelling. De novo 3D protein structures modelling (Rosetta), homology-based modelling (Modeller), molecular mechanics methods.Chemoinformatics QSAR/QSPR model development and usage for activity predictionand virtual screening. Machine-learning methods (artificial neuronal networks, naive Bayes classifiers, SVM, k-Nearest Neighbors, Ant colony and Random Forest). Regression analysis, principal component analysis. 3D- QSAR methods: ComFA, CoMSIA, Open3D QSAR. 2D-QSAR: Molecular Field Topology Analysis (MFTA). Calculation and usage of different structure-based and property- based molecular descriptors.Structure-based drug design Docking, de novo design, scaffold replacement.Ligand-based drug design Ligand-based screening (ROCS, shape- based etc.). Pharmacophoremodels construction and pharmacophore-based screening.ADME / Tox Liver metabolism, adsorption, efflux, toxicity, solubility optimizationPC skills (GastroPlus, ADMET predictor, MedChemStudio, different software for CYP metabolism prediction, LogP, PSA and other PK-related properties assessment, modelling and optimization). Multiple operational systems and virtual machines, work on clusterwith MPI parallel computing applications (MSU Chebyshev, cluster Titan in Oslo), working with distributed volunteer computing (Drugdiscovery@home project). Medicinal chemistry, organic synthesis retro-synthetic analysis. PHP, Perl, Python Show less

• 

  Digital Bio Pharm limited

  Nov 2015 - May 2016

  Co-founder

  The organization for management of Drugdiscovery@home operations and development, dormant company now.

• 

  SONM • Global fog computing platform

  May 2016 - May 2017

  Co-Founder
• 

  Voronkov Ventures

  Sept 2017 - now

  Founder
• 

  IEO Agency

  Apr 2019 - Dec 2019

  Co-Founder
• 

  UniDAO

  May 2019 - now

  Co-Founder
• 

  Liberland

  Oct 2019 - now

  Representative to Russia for Free Republic of Liberland
• 

  Reloxar

  Nov 2022 - now

  Founder

  Relocation consulting

• 

  TILATA

  Dec 2022 - now

  Blockchain and crypto can help to empower global online communities and bring human creativity and efficiency to a new level! TILATA is the solution towards this decentralized future. Based on blockchain technology, open source and a module structure, TILATA provides all necessary tools needed for creating and managing DeSocs – including law modules working with smart contracts, court modules to enforce these laws, DeFi modules for jurisdiction treasury management, social insurance and network frameworks, launchpads for crypto tokens, modules for NFT-based identities and many more. Show less

  • Founder

    Jun 2023 - now

  • Founder

    Dec 2022 - now